Moreover, the ablation of FAP+α‐SMA+ CAFs in pancreatic cancer has paradoxically accelerated tumor progression, highlighting the complexity and potential risks of indiscriminate CAF targeting. The gene discussed is ACTA1; the disease is pancreatic neoplasm.